PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples
Cancer Biomarkers · 2023
DOI: 10.3233/cbm-220030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, 2023. Verfasst von Katharina Möller und 28 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: B7-H1 Antigen, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND: Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number of tumor types, but a unanimous picture on PD-L1 expression across cancer types is lacking. MATERIALS AND METHODS: We analyzed immunohistochemical PD-L1 expression in 11,838 samples from 118 human tumor types and its relationship with tumor infiltrating CD8 positive lymphocytes. RESULTS: At a cut-off level of 10% positive tumor cells, PD-L1 positivity was seen in 85 of 118 (72%) tumor types, including thymoma (100% positive), Hodgkin’s lymphoma (93%), anaplastic thyroid carcinoma (76%), Kaposi sarcoma (71%), sarcomatoid urothelial carcinoma (71%), and squamous cell carcinoma of the penis (67%), cervix (65%), floor of the mouth (61%), the lung (53%), and pharynx (50%). In immune cells, PD-L1 positivity was detectable in 103 (87%) tumor types, including tumors of haematopoetic and lymphoid tissues (75% to 100%), Warthin tumors of the parotid glands (95%) and Merkel cell carcinoma (82%). PD-L1 positivity in tumor cells was significantly correlated with the number of intratumoral CD8 positive lymphocytes across all tumor types as well as in individual tumor types, including serous carcinoma of the ovary, invasive breast carcinoma of no special type, intestinal gastric adenocarcinoma, and liposarcoma (p< 0.0001 each). CONCLUSIONS: PD-L1 expression in tumor and inflammatory cells is found in a wide range of human tumor types. Higher rates of tumor infiltrating CD8 positive lymphocytes in PD-L1 positive than in PD-L1 negative cancers suggest that the antitumor immune response may trigger tumoral PD-L1 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany.
- Institute of Pathology, Clinical Center Osnabrueck, Osnabrueck, Germany.
Zitieren
APA
Möller, K., Knöll, M., Bady, E., Schmerder, M. J., Rico, S. D., Kluth, M., Hube-Magg, C., Blessin, N. C., Mandelkow, T., Lennartz, M., Menz, A., Luebke, A. M., Höflmayer, D., Fraune, C., Bernreuther, C., Lebok, P., Uhlig, R., Contreras, H., Weidemann, S., …, & Krech, T. (2023). PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples. Cancer Biomarkers. https://doi.org/10.3233/cbm-220030
Vancouver
Möller K, Knöll M, Bady E, Schmerder MJ, Rico SD, Kluth M, et al. PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples. Cancer Biomarkers. 2023. doi:10.3233/cbm-220030
BibTeX
@article{Mller2023,
author = {Möller, Katharina and Knöll, Madeleine and Bady, Elena and Schmerder, Max Jonathan and Rico, Sebastian Dwertmann and Kluth, Martina and Hube-Magg, Claudia and Blessin, Niclas C and Mandelkow, Tim and Lennartz, Maximilian and Menz, Anne and Luebke, Andreas M and Höflmayer, Doris and Fraune, Christoph and Bernreuther, Christian and Lebok, Patrick and Uhlig, Ria and Contreras, Hendrina and Weidemann, Sören and Gorbokon, Natalia and Jacobsen, Frank and Clauditz, Till S and Steurer, Stefan and Burandt, Eike and Minner, Sarah and Sauter, Guido and Simon, Ronald and Marx, Andreas H and Krech, Till},
title = {PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples},
journal = {Cancer Biomarkers},
year = {2023},
doi = {10.3233/cbm-220030}
}
EUVIMED